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Lipid-lowering trials involving haemodialysis patients 
 
The German Diabetes and Dialysis (or “4D”) Study, addressed whether 
lowering low density lipoprotein (LDL) cholesterol with statin therapy would 
reduce cardiovascular events in haemodialysis patients with type II diabetes. 
Between March 1998 and October 2002, the 4D investigators randomly 
allocated 1,255 patients at 178 dialysis centres throughout Germany to either 
atorvastatin 20 mg or placebo. The primary endpoint was a composite of 
death due to cardiac causes, non-fatal myocardial infarction and stroke. The 
study was terminated in March 2004 after the pre-specified 424 endpoints had 
been recorded during a median follow-up of 4 years. Despite a 42% reduction 
in LDL cholesterol concentration (compared to 1.5% with placebo), 
atorvastatin had no statistically significant effect on the composite primary 
endpoint, which was recorded in 226 patients randomized to atorvastatin as 
compared to 243 patients assigned to placebo (relative risk 0.92, 95% 
confidence interval 0.77 to 1.10, p=0.37) [1]. 
 
Taken in the context of accumulating evidence that statins reduced 
cardiovascular events in populations without stage 5 CKD [2], the results of 
4D were controversial. However, they were supported by data from A Study to 
Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An 
Assessment of Survival and Cardiovascular Events (AURORA), published just 
4 years later. The AURORA investigators randomly allocated 2776 
haemodialysis patients, approximately 25% of whom had diabetes, to 
rosuvastatin 10 mg or placebo. They reported a non-significant 6% reduction 
in a composite endpoint very similar to that used in 4D (but including death 
due to vascular as well as cardiac causes) among patients randomized to 
rosuvastatin (hazard ratio 0.96; 95% confidence interval 0.84 to 1.11; P=0.59) 
[3]. 
 
At a time when many nephrologists were starting to abandon statin treatment 
in haemodialysis patients, the Study of Heart and Renal Protection (SHARP) 
reported a 17% reduction in cardiovascular events specifically attributable to 
atherosclerotic disease among 9270 patients with chronic kidney disease, 
including 2527 haemodialysis patients randomly allocated to simvastatin 20 
mg plus ezetimibe 10 mg as compared to placebo (rate ratio 0·83, 95% CI 
0·74-0·94; log-rank p=0·0021) [4]. In contrast to 4D and AURORA, the 
primary endpoint in the SHARP study, a composite of non-fatal myocardial 
infarction or death due to coronary artery disease, non-haemorrhagic stroke, 
or any revascularization procedure, was selected to reflect events likely to 
result from underlying atherosclerotic arterial disease.  The SHARP study was 
not powered to separately assess the impact of LDL cholesterol lowering in 
the haemodialysis population, but clinicians remaining loyal to the 4D and 
AURORA results noted that the impact of LDL-lowering was less marked 
among the 3023 SHARP participants who were receiving dialysis at the time 
of randomization (including 496 on peritoneal dialysis). However, this trend 
was not statistically significant and may be largely explained by the poorer 
compliance with study medication in the dialysis subgroup.  
 
The LDL-weighted proportional effects of statin or statin-based therapy on 
specific atherosclerosis-related vascular outcomes are statistically 
comparable in 4D, AURORA and SHARP [4]. In other words, the impact of 
LDL-lowering on complications of atherosclerosis was similar in all three 
studies. The absence of significant reductions in cardiovascular events 
observed in 4D and AURORA may simply reflect a smaller patient population 
and the fact that the primary outcomes included fewer events attributable to 
atherosclerosis and therefore amenable to lipid lowering intervention.  
 
Faced with the available data, which had been subject to meta-analysis [5], 
(figure 1) the workgroup assigned to write the Kidney Disease Improving 
Global Outcomes (KDIGO) Clinical Practice Guideline for Lipid Management 
in Chronic Kidney Disease recommended that a statin or statin-based lipid-
lowering regimen should not be commenced in patients receiving dialysis, but 
that if patients were already on these therapies, they should be continued [6].  
 
 
 
 
New data from extended follow-up of 4D patients 
 
In this issue of Kidney International, the 4D study investigators publish the 
results of a long-term follow-up of their original patient cohort [7]. This new 
analysis covers a median of 11.4 years, with subjects being randomly 
allocated to atorvastatin versus placebo for only the first 4 years. Once the 
study closed, treatment was left to the discretion of the physicians responsible 
for the care of the patients. In the post randomization period, approximately 
50% of study participants were prescribed statins, this proportion being similar 
in the two original groups, as were their LDL cholesterol concentrations during 
the post study period. Collection of follow-up end-point data involved sending 
questionnaires to healthcare professionals who had current contact with the 
study participants or to participant’s relatives. The investigators also obtained 
data from hospital records and death certificates. The response rate to the 
questionnaires was very high (over 95%) with information obtained on all but 
20 of the original 1255 participants.  
 
During the extended 11 year follow-up period, when considering the original 
primary composite endpoint of the 4D study (death due to cardiac causes, 
non-fatal myocardial infarction and stroke), there was again no significant 
difference when comparing groups previously allocated to atorvastatin or 
placebo, with a relative risk almost identical to that observed in the original 
analysis (0.91, 95% confidence interval 0.78-1.07, p=0.256). Whilst during the 
randomized phase of the study, atorvastatin did not impact on any of the 
individual components of composite primary endpoint (except for an increase 
in fatal stroke in those randomly allocated to atorvastatin), after the extended 
follow-up there were fewer fatal cardiac events in this group (0.80, 95% CI 
0.66-0.97, p=0.02). There was also a reduction in all cardiac events combined 
(0.83, 95% CI 0.7-0.97, p=0.019), reflecting the nominally significant reduction 
in this endpoint reported in the original analysis. Reassuringly, during 
extended follow-up, prior atorvastatin treatment did not modify the risk of 
stroke overall or fatal stroke. The extended follow-up also provides additional 
safety data with no differences in cancer risk, non-vascular death, all-cause 
mortality and no cases of rhabdomyolysis reported. There was also no 
difference in cause specific mortality when comparing the two groups.  
 
Strengths and weaknesses of this new analysis  
 
These findings replicate the original trial results with relative risks that are 
almost identical to those obtained during the randomized phase of the study. 
The major strength of the new analysis is the duration of follow-up, possibly 
the longest for any randomized trial involving haemodialysis patients. As the 
authors remind us, their results reflect those observed during extended follow-
up of cohorts recruited into other statin studies, in which differences in risk 
attributable to LDL lowering persist for several years after the randomized 
phase has been completed [8].  
 
The 4D investigators recognize the potential limitations of their unblinded post 
hoc analysis, but point out that the high response rate to the questionnaires, 
which was equal in the two groups (97.5% return rate for patients previously 
randomized to Atorvastatin as compared to 96.5% for placebo), would have 
minimized the likelihood of bias. However, it remains possible that knowledge 
of prior treatment assignment might have influenced post randomization 
reporting of endpoints by physicians. The authors conducted an analysis to 
check for competing risks by other causes of death, but this did not change 
their results. Further follow-up of the cohort is unlikely to change the 
conclusions because, in keeping with the high level of risk in this group, only 
81 of the original 1255 participants are yet to experience a cardiovascular 
event.  
 
The new data in the context of our current knowledge 
 
These new data endorse the original conclusions of the 4D study. The 
decision to start statin therapy in an individual haemodialysis patient should 
take into consideration the likely contribution of atherosclerotic disease to 
future cardiovascular events. Atherosclerosis is one of several pathological 
processes underlying cardiovascular events in the haemodialysis population 
[9], and the benefits of LDL-lowering (which include decreased plaque size 
and increased plaque stability) will be diluted by the progression of other 
pathological processes which lead to non-atherosclerotic events. Alternative 
interventions, for example to reduce myocardial fibrosis, are also required to 
reduce the clinical burden of cardiovascular disease. Many of the 
cardiovascular events captured in 4D, both during the original study and 
extended follow-up, had their origins in non-atherosclerotic pathologies. As 
shown in the SHARP study, selection of endpoints more directly relevant to 
atherosclerotic narrowing of arteries might have resulted in a different trial 
outcome, assuming that a sufficient number of relevant events occurred. 
 
Where should we go from here?  
 
It seems unlikely that there will be more trials comparing statin therapy to 
placebo in the haemodialysis population, although we may learn more from 
the trials that have been completed. Extended follow-up of SHARP 
participants is ongoing, and it may be possible to further evaluate the true 
benefits of statins by meta-analysis of the 4D, AURORA and SHARP studies, 
including extended follow-up data. Alternatively, the availability of monoclonal 
antibodies that inhibit proprotein convertase subtilisin–kexin type 9 (PCSK9) 
allow greater LDL-reductions (when used in combination with statins) and if 
safe in the haemodialysis population, may help to tease out the benefits of 
stabilizing atherosclerotic plaque in the context of the other pathological 
processes that damage the cardiovascular system. Finally, it is possible that 
reducing the high non-atherosclerotic disease mortality burden of 
haemodialysis patients in the future could enable more patients to survive 
longer and thereby enjoy greater benefits from reductions in LDL cholesterol 
and atherosclerotic disease events. 
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